Liquid Biopsies is a minimally invasive cancer diagnostic test that analyze bodily fluids, primarily blood, to gather information about a tumor, particularly its genetic makeup and potential for treatment.

Market outlook
The expected market to expand from a valuation of USD 7.0 billion in 2025, and reach to USD 8.1 billion 2026 and USD 29.8 billion by 2035, with a CAGR of about 15.6% during this period.

Market drivers:

• Technological Advancements: The continuous advancement in technologies like digit PCR, next-generation sequencing (NGS) and accuracy of liquid-biopsy tests, while expanding their application and improving the diagnostic capabilities .
• Multi cancer Detection (MCD) test : Galleri test employs a simple blood draws that identifies circular tumor DNA. The test can detect multiple cancer types, including pancreatic,esophageal, ovarian, and liver. Also the test can screen cancer before symptoms arise and can identify the disease origin
• Early Cancer Detection: Liquid biopsies allow for earlier cancer detection  compared to the traditional methods, which enables timely interventions on potential level improving patient outcomes.
• Increased Benefits Over Conventional Biopsy: This minimal invasive process not only offers reducing patient discomfort and quicker recovery but also ability to track tumor growth and therapeutic responses in no time.

Challenges:

• High cost: The cost of reagent, equipment and labor impacts the affordability.
• Technical limitations: Lacking of standardization and validation of different isolation techniques.
• Limited sensitivity for early detection.

Start-ups paving the way:

Thrive Earlier Detection:-

 Founded in 2020, is a provider of a blood-based liquid biopsy test for treatment of cancer.

Company offers a liquid biopsy-based test for multiple cancer detection.

This test analyze DNA mutations and protein abnormalities associated with cancer.

C2i Genomics:

It is a provider of liquid biopsy for post-cancer surgery monitoring and also provides tool for cancer tumor monitoring.

It identifies changes in genetic patterns across the entire tumor.

Future advancements in liquid biopsies will integrate multi-omics, AI, and ultra-sensitive detection to enable real-time, non-invasive diagnostics for cancer and beyond.

What’s your take? Let’s discuss.